ArticleWorld journal of gastroenterology2009
Gastric carcinoids: between underestimation and overtreatment.
Article in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 54 citations in OpenAlex.
- Characterization of neuroendocrine cell hyperplasia in autoimmune gastritis: improving H&E-based diagnosis through systematic training.BMC gastroenterology · 2026Article
- Review
- Differences in Endoscopic Features of Gastric Neuroendocrine Tumor and Neuroendocrine Carcinoma From a Clinicopathological Perspective.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- A single center retrospective analysis of feasibility of diagnostic endoscopic resection for grade 1 or 2 gastric neuroendocrine tumors.Scientific reports · 2025Article
- Current study of pathogenetic mechanisms and therapeutics of chronic atrophic gastritis: a comprehensive review.Frontiers in cell and developmental biology · 2024Review
- Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome.Annals of surgical oncology · 2021Article
- Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.Endocrine-related cancer · 2019Article
- Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).Endocrine · 2017Article
- Management of gastric and duodenal neuroendocrine tumors.World journal of gastroenterology · 2016Review
- [Surgical approach of gastroduodenal neuroendocrine neoplasms].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2016Review
- Endoscopic diagnosis and management of type I neuroendocrine tumors.World journal of gastrointestinal endoscopy · 2015Review
- Clinical features and management of type I gastric carcinoids.Clinical journal of gastroenterology · 2014Review
- Long-term follow up of endoscopic resection for type 3 gastric NET.World journal of gastroenterology · 2013Article
- Article
- Current concepts on gastric carcinoid tumors.Gastroenterology research and practice · 2012Article
- Biomagnetic techniques for evaluating gastric emptying, peristaltic contraction and transit time.World journal of gastrointestinal pathophysiology · 2011Article
- [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2011Review
- Type 1 Gastric Carcinoid in the Indian Population and Its Association with Multifocal Gastric Atrophy.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinoids (GCs), which originate from gastric enterochromaffin-like (ECL) mucosal cells and account for 2.4% of all carcinoids, are found increasingly in the course of upper gastrointestinal tract endoscopy. Current nosography includes those occurring in chronic conditions with hypergastrinemia, as the type 1 associated with chronic atrophic gastritis, and the type 2 associated with Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1, and type 3, which is unrelated to hypergastrinemia and is frequently malignant, with distant metastases. The optimal clinical approach to GCs remains to be elucidated, depending upon type, size and number of carcinoids. While there is agreement concerning the treatment of type 3 carcinoids, for types 1 and 2, current possibilities include simple surveillance, endoscopic polypectomy, surgical excision, associated or not with surgical antrectomy, or total gastrectomy. Moreover, the recent introduction of somatostatin analogues represents a therapeutic option of possibly outstanding relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.